402925-01-3

Upstream product

• 110-91-8 morpholine 
• 402925-00-2 2-{[4-(2-acetylamino-2-allyloxycarbonyl-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid benzhydryl ester 
• 402924-99-6 2-{[4-(2-acetylamino-2-allyloxycarbonyl-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid 
• 592531-95-8 2-[4-(2-acetylamino-2-allyloxycarbonylethyl)-2-ethylphenylamino]-benzoic acid 
• 436864-41-4 benzyl (2E)-2-(acetylamino)-3-(4-amino-3-ethylphenyl)-2-propenoate 
• 402924-97-4 2-acetylamino-3-(4-amino-3-ethyl-phenyl)-propionic acid 

Downstream Products

• 402925-25-1 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester 
• 592532-29-1 2-({4-[2-acetylamino-2-(4-chloro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl}-tert-butoxyoxalyl-amino)-benzoic acid benzhydryl ester 
• 592532-31-5 2-({4-[2-acetylamino-2-(4-methoxy-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl}-tert-butoxyoxalyl-amino)-benzoic acid benzhydryl ester 
• 402925-03-5 2-[(4-{2-acetylamino-2-[4-(2-trimethylsilanyl-ethoxycarbonyl)-butylcarbamoyl]-ethyl}-2-ethyl-phenyl)-tert-butoxyoxalyl-amino]-benzoic acid benzhydryl ester 
• 402925-04-6 2-({4-[2-acetylamino-2-(4-carboxy-butylcarbamoyl)-ethyl]-2-ethyl-phenyl}-tert-butoxyoxalyl-amino)-benzoic acid benzhydryl ester 
• 592532-36-0 2-({4-[2-acetylamino-2-(4-phenethylcarbamoyl-butylcarbamoyl)-ethyl]-2-ethyl-phenyl}-tert-butoxyoxalyl-amino)-benzoic acid benzhydryl ester 
• 592532-57-5 2-[(4-{2-acetylamino-2-[4-(1-methoxycarbonyl-3-methylsulfanyl-propylcarbamoyl)-butylcarbamoyl]-ethyl}-2-ethyl-phenyl)-tert-butoxyoxalyl-amino]-benzoic acid benzhydryl ester 
• 592532-38-2 2-[(4-{2-acetylamino-2-[4-(1-carbamoyl-2-phenyl-ethylcarbamoyl)-butylcarbamoyl]-ethyl}-2-ethyl-phenyl)-tert-butoxyoxalyl-amino]-benzoic acid benzhydryl ester 

Relevant academic research and scientific papers

Potent, selective inhibitors of protein tyrosine phosphatase 1B

We have previously reported a novel series of oxalyl-aryl-amino benzoic acid-based, catalytic site-directed, competitive, reversible protein tyrosine phosphatase 1B (PTP1B) inhibitors. With readily access to key intermediates, we utilized a solution phase

Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors

Compounds of formula (I) or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP1B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.